Revolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus Nanoparticles
Sector: Raw Materials • Location: Italy
Source: EU Funding & Tenders Portal
At Diamante Società Benefit srl we leverage our proprietary Plant Molecular Farming Platform to develop cutting-edge treatments for autoimmune diseases through virus nanoparticles (VNP). Our patented protected VNPs’ mode of action is based on Antigen Specific Immunotehrapy. This means that our VNPs are able to re-educate the immune system to immune tolerate the specific body’s own cell (autoantige
Project Information FAQ
Project Information
Want to explore the full details? View the full report
Participants
Sponsoring Agency | Obfuscated Data |
Company | Obfuscated Data |
Status
Original status | ongoing |
Taiyo status | Obfuscated Data |
Taiyo last update | 00-00-0000 |
Available timestamps | 00-00-0000 |
Available timestamp type | Obfuscated Data |
Contact
Contact name | Obfuscated Data |
Phone | 0000000000 |
ObfuscatedData@email.com | |
Address | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Description
Description | At Diamante Società Benefit srl we leverage our proprietary Plant Molecular Farming Platform to develop cutting-edge treatments for autoimmune diseases through virus nanoparticles (VNP). Our patented protected VNPs’ mode of action is based on Antigen Specific Immunotehrapy. This means that our VNPs are able to re-educate the immune system to immune tolerate the specific body’s own cell (autoantigen) causing the disease. Our Proof-of-concept studies in Rheumatoid Arthritis (RA - our first indication) animal models have shown complete remission of arthritic symptoms. Currently, there is no cure or preventive measure for this chronic condition; first-line treatments revolve around immunosuppression, causing several side effects. Our drug will be the first treatment based on the restoration of self-tolerance, while maintaining the immune system’s ability to defend itself; hence reducing potential harmful side effects. We are now seeking funding to cover the next clinical development steps. |
Original sub-sector | Obfuscated |
Original Currency | USD |
Original budget | 000000000000000 |
Procurement method | Obfuscated Data |
Budget | 000000000000000 |
Location
Region | Obfuscated |
Country | Obfuscated |
State | Obfuscated Data |
County | Obfuscated |
Location | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Source
Source reliability | High |
Data quality score | 100% |
Source | Obfuscated Data |
URL | obfuscated_data,obfuscateddata.com |
More Details
Project Type | Obfuscated Data |
Article Published Date | Obfuscated Data |
